Addex Therapeutics - ADXN Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12 month target prices for Addex Therapeutics' stock. Their ADXN share price forecasts range from $15.00 to $15.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,263.6% from the stock's current price.
View analysts price targets for ADXN or view top-rated stocks among Wall Street analysts.

Addex Therapeutics' stock was trading at $0.6301 at the beginning of 2023. Since then, ADXN stock has increased by 74.6% and is now trading at $1.10.
View the best growth stocks for 2023 here.

Addex Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 338,700 shares, an increase of 149.8% from the February 13th total of 135,600 shares. Based on an average daily volume of 304,500 shares, the short-interest ratio is presently 1.1 days.
View Addex Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ADXN earnings forecast.

Addex Therapeutics Ltd (NASDAQ:ADXN) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, hitting analysts' consensus estimates of ($0.72). The firm had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.42 million. Addex Therapeutics had a negative net margin of 1,737.41% and a negative trailing twelve-month return on equity of 190.82%. During the same quarter in the previous year, the business posted ($0.78) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced Biomedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

Addex Therapeutics trades on the NASDAQ under the ticker symbol "ADXN."

Addex Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (8.40%) and Susquehanna International Group LLP (0.56%).

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADXN stock can currently be purchased for approximately $1.10.

Addex Therapeutics (NASDAQ:ADXN) has a market capitalization of $14.14 million and generates $1.23 million in revenue each year. The company earns $-16,800,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.

Addex Therapeutics' mailing address is CHEMIN DES AULX 12 PLAN-LES-OUATES, GENEVA V8, CH-1228. The official website for the company is www.addextherapeutics.com. The company can be reached via phone at 011-41-22-884-1555, via email at investor.relations@addextherapeutics.com, or via fax at 41-22-884-1556.